The safety and efficacy of ALLERVAX CAT in cat allergic patients

Clinical Immunology

Volumn 93, Issue 3, 1999, Pages 222-231

  Maguire, Peter ^a   Nicodemus, Christopher ^b   Robinson, Donna ^b   Aaronson, Don ^c   Umetsu, Dale T ^a  

^a STANFORD UNIVERSITY   (United States)

^b ImmuLogic Pharmaceutical Corporation   (United States)

^c NONE

Author keywords

Allergy; ALLERVAX; Asthma; Cat; Immunotherapy

Indexed keywords

ALLERGEN; ALLERVAX; ANTIALLERGIC AGENT; EPITOPE; PLACEBO; UNCLASSIFIED DRUG;

ALLERGY; ANAPHYLAXIS; ARTICLE; ASTHMA; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDER; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032787366     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4795     Document Type: Article

References (34)

1. Gergen P. J., Turkeltaub P. C., Kovar M. G. The prevalence of allergic skin test reactivity to eight common aeorallergens in the U.S. population: Results from the second National Health and Examination Survey. J. Aller. Clin. Immunol. 80:1987;669-679.
2. Counsell C. M., Bond J. F., Ohman J. L., Greenstein J. L., Garman R. D. Definition of the human T-cell epitopes of Fel d1, the major allergen of the domestic cat. J. Aller. Clin. Immunol. 98:1996;884-894.
3. Lind P., Norman P. S., Newton M., Lowenstein H., Schwartz B. The prevalence of indoor allergens in the Baltimore area: House dust-mite and animal-dander antigens measured by immunochemical techniques. J. Aller. Clin. Immunol. 80:1987;541-547.
4. Ohman J. L. Jr., Findlay S. R., Leiterman K. M. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J. Aller. Clin. Immunol. 74:1984;230-239.
5. Van Metre T. E., Marsh D. G., Adkinson N. F., Kagey-Sobotka A., Khattignavong A., Norman P. S., Rosenberg G. L. Immunotherapy for cat asthma. J. Aller. Clin. Immunol. 82:1988;1055-1068.
6. Bousquet J., Michel F. Specific immunotherapy in asthma: Is it effective? J. Aller. Clin. Immunol. 94:1994;1-11.
7. Bond J. F., Brauer A. W., Segal D. B., Nault A. K., Rogers B. L., Kuo M. C. Native and recombinant Fel d1 as probes into the relationship of allegen structure to human IgE immunoreactivity. Mol. Immunol. 30:1993;1529-1541.
8. Norman P. S., Ohman J. L. Jr., Long A. A., Creticos P. S., Gefter M. A., Shaked Z., Wood R. A., Eggleston P. A., Hafner K. B., Rao P. Treatment of cat allergy with T-cell reactive peptides. Am. J. Resp. Crit. Care Med. 154:1996;1623-1628.
9. Creticos P. S., Spector S. L., Busse W. W., Israel E., Nicodemus C. F., Jones N. H., Olson T., Gefter M. L., Lichtenstein L. M., Norman P. S. Evaluation of T cell epitope defined peptides from cat allergen by bronchial challenge. J. Aller. Clin. Immunol. 95:1995;390 (A).
10. Marcotte G. V., Braun C. M., Norman P. S., Nicodemus C. F., Kagey-Sobotka A., Lichtenstein L. M., Essayan D. M. Effects of peptide therapy on ex vivo T-cell responses. J. Aller. Clin. Immunol. 101:1998;506-513.
11. Pene J., Desroches A., Paradis L., Lebel B., Farce M., Nicodemus C. F., Yssel H., Bousquet J. Immunotherapy with Feld 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Aller. Clin. Immunol. 101:1998;571-578.
12. van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bull. Int. Stat. Inst. 37:1958;351-361.
13. Norman P. S., Lichtenstein L. M., Ishizaka K. Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, and basophil histamine release. J. Aller. Clin. Immunol. 52:1973;210-224.
14. Greineder D. Risk management in allergen immunotherapy. J. Aller. Clin. Immunol. 98:1996;S330-S334.
15. Greenberg M. A., Kaufman C. R., Gonzalez G. E., Rosenblatt C. D., Smith L. J., Summers R. J. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J. Aller. Clin. Immunol. 77:1986;865-870.
16. Lin M. S., Tanner E., Lynn J., Friday G. A. Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann. Allergy. 71:1993;557-562.
17. Portnoy J., Bagstad K., Kanarek H., Pacheco F., Hall B., Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann. Allergy. 73:1994;409-418.
18. Hejjaoui A., Ferrando R., Dhivert H., Michel F. B., Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J. Allergy Clin. Immunol. 89:1992;925-933.
19. Briner T. J., Kuo M.-C., Keating K. M., Rogers B. L., Greenstein J. L. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d1. Proc. Natl. Acad. Sci. USA. 90:1993;7608-7612.
20. Hoyne G. F., O'Hehir R. E., Wraith D. C., Thomas W. R., Lamb J. R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178:1993;1783-1788.
21. Nicodemus, C. F., Tolerogenic peptides. InTherapeutic Immunology (Austen, K. F., Burakoff, S. J., Rosen, F. S., and Strom, T. B., Eds). pp. 628-635, Blackwell Sci. Cambridge.
22. Norman P. S. Modern concepts of immunotherapy. Curr. Opin. Immunol. 5:1993;968-973.
23. Creticos P. S., Reed C. E., Norman P. S., Khoury J., Adkinson N. F. J., Buncher C. R., Busse W. W., Bush R. K., Gadde J., Li J. T. Ragweed immunotherapy in adult asthma. New Engl. J. Med. 334:1996;501-506.
24. Creticos P. S. Immunotherapy with allergens. J. Am. Med. Assoc. 268:1992;2834-2839.
25. Iliopoulos O., Proud D., Adkinson N. F. Jr., Creticos P. S., Norman P. S., Kagey-Sobotka A., Lichtenstein L. M., Naclerio R. M. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: Changes in inflammatory mediators and cells. J. Aller. Clin. Immunol. 87:1991;855-866.
26. Adkinson N. F. Jr., Eggleston P. A., Eney D., Goldstein E. O., Schuberth K. C., Bacon J. R., Hamilton R. G., Weiss M. E., Arshad H., Meinert C. L., Tonascia J., Wheeler B. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 336:1997;324-331.
27. Abramson M. J., Puy R. M., Weiner J. M. A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med. 151:1995;969-974.
28. Benjaponpitak S., Oro A. S., Maguire P., DeKruyff R. H., Umetsu D. T. The kinetics of changes in cytokine production by CD4+ T cells during conventional allergen immunotherapy. J. Aller. Clin. Immunol. 103:1999;468-475.
29. Hanania N. A., Chapman K. R., Sturtridge W. C., Szalai J. P., Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Aller. Clin. Immunol. 96:1995;571-579.
30. Volovitz B., Amir J., Malik H., Kauschansky A., Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N. Engl. J. Med. 329:1993;1703-1708.
31. Garbe E., LeLorier J., Boivin J. F., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. J. Am. Med. Assoc. 277:1997;722-727.
32. Cumming R. G., Mitchell P., Leeder S. R. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med. 337:1997;8-14.
33. Josefson D. Asthma drug linked with Churg-Strauss syndrome. Br. Med. J. 315:1997;330.
34. Secrist H., Chelen C. J., Wen Y., Marshall J. D., Umetsu D. T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 178:1993;2123-2130.